IGI Logo

Granules India is currently trading at Rs. 451.00, up by 19.80 points or 4.59% from its previous closing of Rs. 431.20 on the BSE.

The scrip opened at Rs. 448.60 and has touched a high and low of Rs. 455.60 and Rs. 442.60 respectively. So far 53333 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 724.55 on 02-Sep-2024 and a 52 week low of Rs. 382.05 on 15-Apr-2024.

Last one week high and low of the scrip stood at Rs. 494.95 and Rs. 412.05 respectively. The current market cap of the company is Rs. 10981.17 crore.

The promoters holding in the company stood at 38.84%, while Institutions and Non-Institutions held 37.59% and 23.55% respectively.

Granules India has completed the acquisition of Senn Chemicals AG, a Switzerland based Contract Development and Manufacturing Organization (CDMO) specializing in peptide development and manufacturing. The company has executed the acquisition through its wholly owned Indian subsidiary -- Granules Peptides which has acquired 100% of the equity of Senn Chemicals from the founding Senn family.

With this acquisition, the company has forayed into the CDMO space, with Senn’s established CDMO business providing a strong platform for growth. The acquisition will enable the company to accelerate the development and manufacturing of GLP-1 receptor agonists and other peptide-based APIs, addressing the growing demand in antidiabetic, anti-obesity, and other next-generation therapeutic areas. Granules and Senn have already initiated joint development activities in this space, with a broader peptide API pipeline planned. The acquisition enhances the company’s global footprint and provides access to a regulated market client base and highly skilled scientific talent in Europe.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages.